Gold prices steady ahead of Fed decision; weekly weakness noted
Masimo (NASDAQ:MASI) is recognized for its innovative monitoring technologies, including measurements, sensors, patient monitors, and automation and connectivity solutions. The company's technology is widely used in healthcare settings globally, and it continues to develop new products and solutions aimed at improving patient outcomes and reducing healthcare costs. With a five-year revenue CAGR of 19% and trading near its 52-week high, Masimo demonstrates strong market positioning. For deeper insights into Masimo's financial health and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which provides detailed analysis of this healthcare technology leader. With a five-year revenue CAGR of 19% and trading near its 52-week high, Masimo demonstrates strong market positioning. For deeper insights into Masimo's financial health and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which provides detailed analysis of this healthcare technology leader. Healthcare revenue is expected to reach around $368 million, with an 8% growth reported and 9% on a constant currency basis. Non-healthcare revenue is projected at approximately $232 million, showing an 11% increase in both reported and constant currency terms.
For the full year of 2024, Masimo expects consolidated revenue to be about $2,094 million, a 2% growth reported and 3% on a constant currency basis. Healthcare revenue for the year is estimated at $1,395 million, representing a 9% increase reported and a 10% rise on a constant currency basis. However, non-healthcare revenue saw a decline of 10% reported and a 9% decrease on a constant currency basis, totaling around $699 million. The company also forecasts non-GAAP earnings per diluted share to exceed $4.10, aligning with the high end of their previous guidance range.
Masimo is recognized for its innovative monitoring technologies, including measurements, sensors, patient monitors, and automation and connectivity solutions. The company's technology is widely used in healthcare settings globally, and it continues to develop new products and solutions aimed at improving patient outcomes and reducing healthcare costs. With a five-year revenue CAGR of 19% and trading near its 52-week high, Masimo demonstrates strong market positioning. For deeper insights into Masimo's financial health and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which provides detailed analysis of this healthcare technology leader. Non-GAAP operating profit is projected to be between $398 million and $406 million, with non-GAAP operating margins of at least 26.5%. Furthermore, the company expects non-GAAP earnings per diluted share to range from $4.90 to $5.10.
The preliminary financial figures are based on current expectations and may be subject to adjustments following customary annual audit procedures. Masimo plans to discuss the complete fourth quarter and full-year 2024 financial results after the market closes on Tuesday, February 25, 2025.
Masimo is recognized for its innovative monitoring technologies, including measurements, sensors, patient monitors, and automation and connectivity solutions. The company's technology is widely used in healthcare settings globally, and it continues to develop new products and solutions aimed at improving patient outcomes and reducing healthcare costs.
The information in this article is based on a press release statement from Masimo Corporation.
In other recent news, Masimo Corporation has seen a series of significant developments. The healthcare technology company retained its Outperform rating from Raymond (NS:RYMD) James, which also increased Masimo's price target from $170.00 to $194.00. The firm's analysts highlighted opportunities for Masimo's margin expansion and anticipated a growth rate of over 15% for the company's earnings per share (EPS) in the coming years.
Furthermore, Masimo announced a strategic shift, focusing on its core healthcare business. This change led to the termination of Tao Levy, the company's Executive Vice President of Business Development. The company also appointed Michelle Brennan as interim Chief Executive Officer for a six-month term.
In terms of financial performance, Masimo reported robust growth in its third quarter of 2024. The company saw a year-over-year increase in healthcare revenues and solid non-GAAP earnings per share growth. Piper Sandler analysts also highlighted Masimo as a top idea, expressing confidence in the company's ability to beat Q4 projections and surpass 2025 consensus estimates.
These recent developments demonstrate Masimo's continued focus on growth and profitability in the healthcare sector. The company's strategic changes and positive financial performance indicate a strong market position and a promising outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.